Although we found a similar correlation between clinical outcome and course of BACE‐1 concentrations after 6 months of treatment as aforementioned for alpha‐synuclein, our overall data regarding BACE‐1 provide no convincing evidence that this protein might reflect pathogenic mechanisms important for SMA. The gene discussed is SNCA; the disease is proximal spinal muscular atrophy.